Nanexa AB (publ) announced that the company is engaging the contract research organization (CRO) Profil, in Neuss, Germany, ahead of the upcoming start of a phase I study with NEX-22, a monthly depot of liraglutide for the treatment of type 2 diabetes and ultimately obesity. Profil is highly specialized in early clinical studies in diabetes and obesity, and has an excellent global reputation for conducting clinical research in these two indications. Profil is a full-scale CRO specializing in early clinical research and translational research in diabetes and obesity.

Since its inception in 1999, the company has been engaged in numerous clinical research studies with some of the world's largest pharmaceutical companies. For its research in these indications, the company has up to 65 beds at its clinic and a team of more than 330 employees, over 25 of whom are physicians. The NEX-22 project is now in the preclinical phase and Nanexa announced earlier this year that a first animal study showed a release of lIRaglutide over 28 days.

Further preclinical studies are now underway, which preliminarily confirm these results. The phase I study of NEX-22 expected to be ready to start around the end of 2023.